Lantern Pharma (LTRN) Tops Q2 EPS by 13c

Lantern Pharma (NASDAQ: LTRN) reported Q2 EPS of ($0.40), $0.13 better than the analyst estimate of ($0.53).

For earnings history and earnings-related data on Lantern Pharma (LTRN) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Rent the Runway (RENT) Reports Q2 Loss of $0.38/sh
• Futuremain to merge with ChampionsGate in $80M Nasdaq deal